DK1349545T3 - Farmaceutiske præparater af fenretinid med öget biotilgængelighed samt fremgangsmåder til anvendelse deraf - Google Patents

Farmaceutiske præparater af fenretinid med öget biotilgængelighed samt fremgangsmåder til anvendelse deraf

Info

Publication number
DK1349545T3
DK1349545T3 DK01989170T DK01989170T DK1349545T3 DK 1349545 T3 DK1349545 T3 DK 1349545T3 DK 01989170 T DK01989170 T DK 01989170T DK 01989170 T DK01989170 T DK 01989170T DK 1349545 T3 DK1349545 T3 DK 1349545T3
Authority
DK
Denmark
Prior art keywords
fenretinide
retinide
methods
pharmaceutical preparations
increased bioavailability
Prior art date
Application number
DK01989170T
Other languages
English (en)
Inventor
Shanker Gupta
B Rao Vishnuvajjala
C Patrick Reynolds
Barry James Maurer
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Application granted granted Critical
Publication of DK1349545T3 publication Critical patent/DK1349545T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01989170T 2000-12-05 2001-12-05 Farmaceutiske præparater af fenretinid med öget biotilgængelighed samt fremgangsmåder til anvendelse deraf DK1349545T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25146300P 2000-12-05 2000-12-05
PCT/US2001/046548 WO2002058689A1 (en) 2000-12-05 2001-12-05 Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same

Publications (1)

Publication Number Publication Date
DK1349545T3 true DK1349545T3 (da) 2009-02-16

Family

ID=22952077

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01989170T DK1349545T3 (da) 2000-12-05 2001-12-05 Farmaceutiske præparater af fenretinid med öget biotilgængelighed samt fremgangsmåder til anvendelse deraf

Country Status (8)

Country Link
US (1) US7169819B2 (da)
EP (1) EP1349545B1 (da)
JP (2) JP4384409B2 (da)
AT (1) ATE414511T1 (da)
DE (1) DE60136648D1 (da)
DK (1) DK1349545T3 (da)
ES (1) ES2316489T3 (da)
WO (1) WO2002058689A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1594544T (pt) * 2003-01-31 2016-07-14 Los Angeles Childrens Hospital Composições orais de fenretinida tendo biodisponibilidade aumentada e métodos de utilização das mesmas
ITMI20032019A1 (it) * 2003-10-17 2005-04-18 Fidia Farmaceutici Microemulsioni di retinoidi e composizioni farmaceutiche che le contengono
BRPI0405798B8 (pt) * 2003-11-28 2021-05-25 Halex Istar Ind Farmaceutica L processo de eliminação de resíduos alcalinos presentes no 9-((1,3-dihidroxipropan-2-iloxi)metil)-2-amino-1h-purin-6(9h)-ona e apresentação farmacêutica
NZ551955A (en) * 2004-06-23 2010-08-27 Revision Therapeutics Inc Methods and compositions for treating ophthalmic conditions with retinyl derivatives
WO2006047475A2 (en) * 2004-10-25 2006-05-04 Sytera, Inc. Detection and analysis of ophthalmically-relevant fluorescent molecules
JP2008519054A (ja) * 2004-11-04 2008-06-05 シリオン セラピューティクス， インコーポレイテッド レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
CA2680606C (en) 2006-03-29 2014-08-05 Wayne State University Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
US7321064B1 (en) 2007-03-08 2008-01-22 Cedarburg Pharmaceuticals, Inc. Preparation of amides of retinoic acid via mixed anhydride and mixed carbonate intermediates
US20100311765A1 (en) * 2007-09-28 2010-12-09 Barry James Maurer Metabolic degradation inhibitors for anti-hyperproliferative agents
US8063020B2 (en) * 2007-12-22 2011-11-22 Simpkins Cuthbert O Resuscitation fluid
US8618056B2 (en) * 2007-12-22 2013-12-31 Cuthbert O. Simpkins Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US8906855B2 (en) * 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
WO2009103166A1 (en) 2008-02-21 2009-08-27 The Royal Institution For The Advancement Of Learning/Mcgill University Treatment of neural diseases or conditions
US8088822B2 (en) * 2008-07-08 2012-01-03 Ji Zhang Use of fenretinide or bioactive derivatives thereof and pharmaceutical compositions comprising the same
EP2174650A1 (en) * 2008-10-08 2010-04-14 Polichem SA Modified release emulsions for application to skin or vaginal mucosa
CN102892748A (zh) * 2009-11-12 2013-01-23 德克萨斯理工大学 用于治疗过度增生性疾病的组合物和方法
BR112013011942A2 (pt) * 2010-11-15 2016-11-01 Univ Michigan formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
CA2817957C (en) * 2010-11-15 2016-05-10 Texas Tech University Substance for increasing the production of a specific acyl-chain dihydroceramide(s) for improving the effectiveness of cancer treatments
WO2016011535A1 (en) 2014-07-25 2016-01-28 Laurent Pharmaceuticals Solid oral formulation of fenretinide
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
WO2022170398A1 (en) * 2021-02-11 2022-08-18 Monash University Formulations for improved bioavailability of fenretinide

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190594A (en) 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
DE3432696A1 (de) * 1984-09-03 1986-03-13 Siemens AG, 1000 Berlin und 8000 München Antriebsvorrichtung fuer einen leistungsschalter mit exzenter und richtgesperre
US4665098A (en) * 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4960799A (en) 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
AU666293B2 (en) * 1990-08-13 1996-02-08 David W. Yesair Mixed lipid-bicarbonate colloidal particles for delivering drugs or calories
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
WO1994011030A1 (en) 1992-11-13 1994-05-26 The Ohio State University Research Foundation C-glycoside analogues of n-(4-hydroxyphenyl)retinamide-o-glucuronide
US5464870A (en) 1993-02-10 1995-11-07 Ortho Pharmaceutical Corporation Methods of inhibiting development of leukoplakia with fenretinide
EP0619116A3 (en) * 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
CA2222161C (en) * 1995-06-06 2002-02-05 Biomolecular Products, Inc. Mixed lipid-bicarbonate colloidal particles for delivering drugs or calories
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
BE1011216A3 (fr) 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
DK1091745T3 (da) 1998-06-29 2008-12-15 Los Angeles Childrens Hospital Behandling af hyperproliferative forstyrrelser
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2002032413A2 (en) * 2000-10-17 2002-04-25 Board Of Regents, The University Of Texas System A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes

Also Published As

Publication number Publication date
EP1349545A4 (en) 2006-05-24
US20020183394A1 (en) 2002-12-05
JP2009292834A (ja) 2009-12-17
EP1349545B1 (en) 2008-11-19
US7169819B2 (en) 2007-01-30
DE60136648D1 (de) 2009-01-02
ATE414511T1 (de) 2008-12-15
JP2005510447A (ja) 2005-04-21
EP1349545A1 (en) 2003-10-08
JP4384409B2 (ja) 2009-12-16
ES2316489T3 (es) 2009-04-16
WO2002058689A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
DK1349545T3 (da) Farmaceutiske præparater af fenretinid med öget biotilgængelighed samt fremgangsmåder til anvendelse deraf
Kawakami et al. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents
EA200400765A1 (ru) Фармацевтические составы, содержащие соединения активного витамина d
Kawakami et al. Solubilization behavior of poorly soluble drugs with combined use of Gelucire 44/14 and cosolvent
MXPA05013278A (es) Composiciones farmaceuticas que comprenden compuestos activos de vitamina d.
WO2005020962A8 (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
EA200601460A1 (ru) Препарат микроэмульсии с высокой концентрацией пропофола для анестезирующих применений
Radomska et al. The use of some ingredients for microemulsion preparation containing retinol and its esters
ATE415943T1 (de) Pharmazeutische zubereitungen enthaltend einen amphoteren emulgator, polyproxylierten cetylalkohol und einen polaren wirkstoff
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
CR7614A (es) Preparaciones de insulina acida con estabilidad mejorada
NO20031901L (no) Farmasöytiske preparater
CA2194226A1 (en) Stable Oil-In-Water Emulsions Incorporating a Taxine (Taxol) and Method of Making Same
KR870002835A (ko) 이온화성 소수성약제의 약제학적 제조방법
DK1259226T3 (da) Anæstetiske formuleringer
NO20025629D0 (no) Formulering
EA200600528A1 (ru) Способ получения водорастворимых дитерпенов и их применение
SE0000774D0 (sv) New formulation
DE60103865D1 (de) Arzneizubereitungen und deren herstellungsverfahren
AP1754A (en) Pharmaceutical compositions based on azetidine derivatives.
MXPA04011990A (es) Composiciones farmaceuticas estabilizadas en la base de aceite de ricino polioxietilado y metodo para fabricar el mismo.
WO2002026208A3 (en) Emulsion vehicle for poorly soluble drugs
HUP0002561A2 (hu) Adalékkompozíció zsírban oldódó vitaminok vizes stabilizálására, az így előállított készítmények, valamint azok alkalmazhatósága különböző területeken
SE0102933D0 (sv) Lipid carrier
ECSP951565A (es) Composiciones farmaceuticas